Department of Hematology, Tokyo Metropolitan Tama Medical Center , Tokyo, Japan .
J Adolesc Young Adult Oncol. 2018 Jun;7(3):389-394. doi: 10.1089/jayao.2017.0120. Epub 2018 Feb 6.
A novel induction therapy, including intensive L-asparaginase, was designed in 2007 for patients aged <45 years with Philadelphia-negative acute lymphoblastic leukemia (ALL). We analyzed seven de novo cases and one case of recurrence who received this treatment. The median age was 21 years (range: 16-35 years). Four patients had T-ALL and the others had B-ALL. All the patients achieved complete remission and proceeded to cord blood transplantation. In the median 72-month follow-up, there were no cases of observed mortality or recurrence. Our results indicate scope for further development of both induction therapy and postremission therapy.
2007 年，为年龄<45 岁的费城染色体阴性急性淋巴细胞白血病（ALL）患者设计了一种新的诱导治疗方案，包括强化 L-门冬酰胺酶。我们分析了 7 例初发患者和 1 例复发患者接受该治疗的情况。中位年龄为 21 岁（范围：16-35 岁）。4 例为 T-ALL，其余为 B-ALL。所有患者均达到完全缓解，并进行了脐带血移植。在中位 72 个月的随访中，无观察到的死亡或复发病例。我们的结果表明，诱导治疗和缓解后治疗均有进一步发展的空间。
